In a fiery address Sunday morning, Desmond Schatz, MD, ADA’s President, Medicine & Science, called diabetes the “epidemic of the 21st century” and urged diabetes care providers to do more to advocate for accelerated research, better reimbursement, and to end the stigma of diabetes. Dr. Schatz said diabetes is an…
Originally appeared in The Post, June 2016. Written by Jill Pease. “Doctors aren’t diagnosing or treating most cases of prediabetes, UF study finds.”…
Originally appeared in The Post, June 2016. Written by Doug Bennett “A UF Health program helps North Florida eat well, access health care and participate in research.”…
Originally appeared in UF News, April 2016 Clayton Mathews, Ph.D., a professor in the College of Medicine, was recently named by the University of Florida Research Foundation as one of 34 UFRF Professors for 2016-2019. This recognition goes to faculty, like…
Desmond Schatz, M.D. and Bimota Nambam, Ph.D. recently released new publications. Both investigators co-authored Immune Intervention in Type 1 Diabetes, which reviews recently published immune interventional and mechanistic studies in T1D subjects. The highlighted publications consist of primary (before the development of islet autoantibodies) and secondary prevention studies…
UFDI Investigator Shahram Salek-Ardakani, Ph.D. and collaborators identified c-Myc as a key controller of memory CD8+ T cells from costimulatory signals.
‘Photovoice’ (photos and captions) was used in this UF study to illustrate the differences in perspective between adolescents and parents regarding living with a child with T1D. The results showcase differences in opinion regarding food-mindfulness, freedom, and more.
The New York Times recently published a feature on the challenges children with type 1 diabetes face in school- read a collection of several parents’ stories here.
UFDI Investigator Michael Haller, M.D. and collaborators found that among overweight adolescents with type 1 diabetes, the addition of metformin to insulin did not improve glycemic control after 6 months.
UF investigators studied the feasibility of the immunoarray platform to screen microparticle- encapsulated adjuvant combinations for the development of improved and personalized vaccines.
